Addition of lenalidomide to melphalan in the treatment of newly diagnosed multiple myeloma: The National Cancer Institute of Canada Clinical Trials Group MY. 11 trial

Current Oncology

Volumn 14, Issue 2, 2007, Pages 61-65

  White, Darrell J ^a,c   Paul, Nancy ^b   Macdonald, David A ^a   Meyer, Ralph M ^b   Shepherd, L E ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c NONE   (Canada)

Author keywords

Lenalidomide; Melphalan; Multiple myeloma; Newly diagnosed; Thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CORTICOSTEROID; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PLACEBO; PREDNISONE; THALIDOMIDE; WARFARIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANADA; CANCER RELAPSE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; IMMUNOMODULATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; VENOUS THROMBOEMBOLISM;

EID: 36649026598     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.2007.107     Document Type: Article

References (22)

1. Ries LAG, Hankey BF, Miller BA, et al., eds. Cancer Statistics Review 1973-88. Bethesda, MD: National Cancer Institute, Division of Cancer Prevention and Control, Surveillance, Epidemiology, and End Results Program; 1991.
2. Osgood EE. The survival time of patients with plasmocytic myeloma. Cancer Chemother Rep 1960;9:1-10.
3. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367: 825-31.
4. Facon T, Mary J, Harousseau J, et al., on behalf of the Intergroupe Francophone du Myelome. Superiority of melphalan-prednisone (MP) ± thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma [abstract 1]. J Clin Oncol 2006;24(pt 1 suppl 18S):1s.
5. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-7.
6. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83.
7. Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long term results of a randomized controlled trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23: 9227-33.
8. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemotherapy for multiple myeloma: final results of phase III in US Intergroup Trial S9321. J Clin Oncol 2006;24:929-36.
9. Anderson KC, Shaughnessy JD Jr, Barlogie B, Harousseau JL, Roodman GD. Multiple myeloma. Hematology Am Soc Hematol Educ Program 2002;:214-40.
10. Singhal S, Mehta J, Desikan R, et al. Antitumour activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
11. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-7.
12. Richardson PG, Jagannath S, Schlossman R, et al. A multi-centre, randomized, phase 2 study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma [abstract]. Blood 2003;102: 825a.
13. Zangari M, Barlogie B, Jacobson J, et al. Revlimid 25 mg × 20 versus 50 mg × 10 q 28 days with bridging of 5 mg × 10 versus 10 mg × 5 as post-transplant salvage therapy for multiple myeloma [abstract]. Blood 2003;102:1642a.
14. Wang M, Knight R, Dimopoulos M, et al. Comparison of lenalidomide in combination with dexamethasone to dexamethasone alone in patients who have received prior thalidomide in relapsed or refractory multiple myeloma [abstract 7522]. J Clin Oncol 2006;24(pt 1 suppl 18S)):427s.
15. Roy V, Bergsagel PL, Allred J, Greipp R. Melphalan, prednisone and lenalidomide combination (MPR) for newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation [abstract]. Blood 2006;108:1016a.
16. Palumbo A, Falco P, Benevolo G, et al. Oral enalidomide plus melphalan and prednisone (R-MP) for newly diagnosed multiplemyeloma [abstract 7518]. J Clin Oncol2006;24(pt 1 suppl 18S):426s.
17. Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002;99:3163-8.
18. Shustik C, Belch A, Robinson S, et al. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Brit J Haematol 2007;136:203-11.
19. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III in study (MM-009) [abstract 7521]. J Clin Oncol 2006;24(pt 1 suppl 18S):427s.
20. Geerts Wh, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Anti-thrombotic and Thrombolytic Therapy. Chest 2004; 126(suppl):3385-400S.
21. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000;355:1295-302.
22. Collaborative overview of randomised trials of antiplatelet therapy - III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308:235-46.